What is liquid biopsy and how is it used for MDS

Liquid Biopsy and MDS: An Educational Overview

What Is Liquid Biopsy?

A liquid biopsy is a blood test that detects cancer cells or cancer-related genetic material (DNA) circulating in your bloodstream. Instead of taking a tissue sample through a needle or surgery, doctors analyze blood to look for signs of disease at the molecular level.

Think of it this way: cancer cells naturally shed genetic material into the blood. A liquid biopsy captures and analyzes this "liquid" evidence of disease, rather than requiring a solid tissue sample.

How It Works:

• Blood is drawn and sent to a laboratory
• Technicians isolate and analyze circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs)
• Genetic sequencing identifies specific mutations present in the cancer cells
• Results help doctors understand the disease's genetic profile

---

Liquid Biopsy in MDS: Current Role

For myelodysplastic syndromes (MDS), liquid biopsy has an important but complementary role rather than a replacement role for bone marrow testing.

Why Liquid Biopsy Matters in MDS:

1. Mutation Detection According to the NCCN Guidelines for MDS (Version 1.2026), genetic testing is a critical part of MDS evaluation. Liquid biopsy can detect mutations in frequently mutated MDS genes including:

• TP53 (associated with poor prognosis)
• ASXL1 (independently associated with poor prognosis)
• RUNX1 (independently associated with poor prognosis)
• SF3B1 (associated with more favorable prognosis)
• DNMT3A, TET2, SRSF2, U2AF1, and others

2. Monitoring Disease Liquid biopsy can track changes in mutation levels over time, helping doctors:

• Monitor how your disease is progressing
• Detect early signs of transformation to acute myeloid leukemia (AML)
• Assess response to treatment

3. Detecting Clonal Hematopoiesis The NCCN Guidelines note that "molecular evidence of clonal hematopoiesis provides information to allow earlier identification of predisposition states for myeloid neoplasms." Liquid biopsy can identify these clonal populations in blood.

---

Important Limitations: Why Bone Marrow Testing Is Still Essential

Liquid biopsy cannot replace bone marrow biopsy for MDS diagnosis and evaluation because:

1. Blast Percentage: MDS classification depends on the percentage of immature blood cells (blasts) in the bone marrow. Liquid biopsy cannot reliably measure this.

2. Morphology Assessment: Doctors need to see the actual appearance and structure of bone marrow cells under a microscope—something only a bone marrow biopsy provides.

3. Cytogenetics: Chromosome analysis (karyotype) requires bone marrow cells and is crucial for MDS risk stratification.

4. Complete Picture: According to NCCN Guidelines, the initial evaluation of MDS requires:

   • Bone marrow aspiration with iron stain
   • Bone marrow biopsy
   • Cytogenetics
   • Molecular testing (which can include liquid biopsy)

---

Current Clinical Use in MDS

Based on available evidence, liquid biopsy in MDS is typically used for:

✅ Supplementary genetic information when bone marrow testing is already being done ✅ Monitoring between bone marrow biopsies ✅ Research studies to better understand disease progression ✅ Detecting mutations that may have prognostic significance

❌ NOT as a standalone diagnostic test for MDS ❌ NOT to replace bone marrow biopsy for initial diagnosis

---

Questions to Ask Your MDS Care Team

If your doctor mentions liquid biopsy, consider asking:

1. "Is liquid biopsy being recommended as part of my initial evaluation, or as a monitoring tool?"
2. "What specific mutations are you looking for, and how will this information change my treatment?"
3. "Will this test replace my bone marrow biopsy, or is it in addition to it?"
4. "How often would you recommend liquid biopsy testing during my follow-up care?"
5. "Are there clinical trials using liquid biopsy for MDS that I might be eligible for?"

---

The Bottom Line

Liquid biopsy is an emerging and valuable tool for MDS that can provide important genetic information and help with disease monitoring. However, it works alongside traditional bone marrow testing, not instead of it. The NCCN Guidelines emphasize that comprehensive MDS evaluation requires multiple testing approaches to give your doctors the complete picture needed for accurate diagnosis and treatment planning.

Your oncologist will determine which tests are most appropriate for your specific situation and how to use the results to guide your care.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.